
    
      A Phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety
      and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute
      Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be due to Gram-Positive
      Organisms.
    
  